Search Results for: "Clinic Roundup"
-
Clinic Roundup
Vaximm AG, of Basel, Switzerland, said top-line data from its Phase I/II dose-escalation study of oral cancer vaccine VXM01 met key safety and tolerability endpointsBioWorld Today | Friday, February 8, 2013 -
Clinic Roundup
Vanda Pharmaceuticals Inc., of Washington, said top-line data from its Phase IIb/III study, dubbed MAGELLAN, testing tasimelteon as a monotherapy in major depressive disorder (MDD) did not meet the primary endpoint of change from baseline in the Hamilton Depression Scale after eight weeks of treatment compared to placeboBioWorld Today | Friday, February 1, 2013 -
Clinic Roundup
Top-line data are expected in the second quarterBioWorld Today | Friday, January 18, 2013 -
Clinic Roundup
Top-line data are expected in the first half of 2014...Stratatech Corp., of Madison, Wis., reported top-line data from a proof-of-concept trial testing StrataGraft, a universal human skin substitute in development for treating severe burnsBioWorld Today | Thursday, January 17, 2013 -
Clinic Roundup
The trial enrolled a total of 234 patients, with top-line data expected by the end of FebruaryBioWorld Today | Tuesday, January 15, 2013 -
Clinic Roundup
Top-line data revealed that at the early clinical evaluation point, between 48 hours and 72 hours of treatment initiation, 90.9 percent of subjects were considered to be stable or improving in investigator assessments, meeting the primary endpoint of the studyBioWorld Today | Tuesday, January 8, 2013 -
Clinic Roundup
As initially reported in December, preliminary top-line data showed that dalbavancin achieved its primary endpoint of noninferiority at 48 to 72 hours following initiation of therapy, as determined by the cessation of spread of the lesion and resolution of feverBioWorld Today | Monday, January 7, 2013 -
Clinic Roundup
Top-line data are expected in mid-2013BioWorld Today | Thursday, December 20, 2012 -
Clinic Roundup
Top-line data are expected in the early spring of 2013BioWorld Today | Wednesday, December 19, 2012 -
Clinic Roundup
Top-line data are expected in the latter part of next yearBioWorld Today | Tuesday, December 18, 2012 -
Clinic Roundup
AcelRx Pharmaceuticals Inc., of Redwood City, Calif., reported top-line data from a Phase III trial demonstrating that the Sufentanil NanoTab PCA System was noninferior (p < 0.001) to intravenous patient-controlled analgesia with morphine for the primary endpoint of Patient Global Assessment (PGA) of method of pain control over the 48-hour study period as determined by the combined percentage of patients with PGA ratings of "good" or "excellent" (78.5 percent vs. 66.1 percent, respectivelyBioWorld Today | Monday, December 17, 2012 -
Clinic Roundup
Biotie Therapies Corp., of Turku, Finland, reported top-line data from a Phase IIb study showing that tozadenant (SYN115), its adenosine A2a antagonist, met the primary endpoint of decreasing the "off" time in Parkinson's patients experiencing levodopa-related end-of-dose wearing off vsBioWorld Today | Wednesday, December 12, 2012 -
Clinic Roundup
Top-line data are expected in early 2013BioWorld Today | Tuesday, December 11, 2012 -
Clinic Roundup
Top-line data are expected to be available in Q1 2013BioWorld Today | Friday, December 7, 2012 -
Clinic Roundup
Top-line data from the PEARL-SC trial, presented in June, showed the drug missed its primary endpoint, defined as clinical improvement at 24 weeks in the SLE responder index, but further data showed that the BAFF inhibitor produced sustained and greater treatment effects vs...The company recently concluded enrollment in its pivotal program, with top-line data expected in the middle of 2013BioWorld Today | Thursday, November 29, 2012 -
Pharma: Clinic Roundup
Pfizer Inc., of New York, said top-line data from a Phase III study testing pregabalin controlled-release (CR) formulation in patients with fibromyalgia indicated that the product had a statistically significant positive effect compared to placebo in the primary endpoint, defined as time to loss of therapeutic responseBioWorld Today | Tuesday, November 20, 2012 -
Clinic Roundup
Top-line data from the PALACE-1 study were reported in July. (See BioWorld Today, July 13, 2012BioWorld Today | Thursday, November 15, 2012 -
Clinic Roundup
Allon is on track to release top-line data from the trial in the second half of DecemberBioWorld Today | Wednesday, November 14, 2012 -
Clinic Roundup
The company reported top-line data from the trial earlier this year. (See BioWorld Today, March 23, 2012BioWorld Today | Thursday, November 8, 2012 -
Clinic Roundup
Top-line data are expected in the second quarter of 2013BioWorld Today | Wednesday, October 17, 2012
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.